BWXT Medical, Bayer AG Ink Agreement On Actinium-225

BWX Technologies Inc's BWXT subsidiary BWXT Medical Ltd. has agreed with Bayer AG BAYRY to develop Actinium-225 (Ac-225) supply and further partnering opportunities on finished products. The financial terms of the agreement were not disclosed.
The companies to broaden their respective commercialization strategies for targeted radionuclide therapies (TRTs) and other products.
Ac-225 is a radioisotope used in targeted alpha therapies (TATs), an emerging class of radionuclide therapy for various tumors with a high unmet medical need.
Bayer's oncology franchise includes six marketed products, including Xofigo and several other TATs in different stages of development.
The parties plan to finalize the terms of the commercial agreements at a later date.
Price Action: BWXT shares traded higher by 1.97% at $55.79 on the last check Thursday.

Overview Rating:

Good

100

0100